glutathione syndrome Nineteen-year follow-up of a patient with severe synthetase deficiency Diseases and Conditions that Glutathione

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

2024 Feb 22;8(1):113

Effect of Tui Na on upper limb spasticity after stroke: a randomized clinical trial

doi: 10.1016/s1382-6689(01)00081-3

NAD is needed to catalyze over 400 enzymes

For the therapy given continuously from day 14 onward, starting after the established ratio deterioration, the deterioration halted within one week, as assessed on day 21, and the ratio then remained constant, and did not deteriorate until the end of the experiment (i.e., day 30) (Figure 1 and Figure 2)